31 results about "Transplantation procedure" patented technology

This invention is directed to novel oxamyl dipeptide ICE / ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

This invention is directed to novel oxamyl dipeptide ICE / ced-3 family inhibitor compounds having the following structure: wherein A, B, R, R1, R1′ p and q are as defined herein. The invention is also directed to pharmaceutical compositions containing one or more of these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated.

A method and composition for enhancing the development of metanephric tissue upon transplantation into an allogenic or xenogenic host are disclosed. Metanephric tissue is removed from an embryonic donor and is contacted with a composition comprising one or more growth factors for metanephric development. The composition can be administered to the metanephric tissue in vitro prior to implantation of the donor tissue in the transplant recipient, or can be administered in vivo either during or subsequent to the transplantation procedure.

The present disclosure relates to methods and systems for processing isolated mammalian tissue for use in surgical grafting, implantation, or transplantation procedures. The method employs electron beam sterilization, the collagen tissue is partially submerged in rHSA (Recombinant Human Serum Albumin), the tissue is stored in specially designed packaging, and the tissue is stored at ambient temperatures without requiring refrigeration. The terminal sterilization using electronic beams takes place in the special packaging. This inventive technology offers advantages including being biologically safe, maintaining tissue integrity while minimizing size, increasing scalability, increasing shelf life, increasing the amount of tissue usable for transplantation, and reducing of costs associated with processing and storing tissue for long periods of time.

The present disclosure relates to methods to deconvolute a mixture sample of genetic material from different origins or sources. The disclosed methods can be used in various applications, including, the non-invasive determination of a fetal genome, a fetal -ome (e.g. exome). or other targeted fetal locus from cell-free nucleic acids in maternal plasma or other body fluids; the determination of cancer-associated mutations from cell-free nucleic acids in a body fluid sample that contains a mixture of nucleic acids from normal cells and tumor cells; and quantification of donor cell contaminationusing a body fluid from a transplantation recipient to monitor and / or predict the outcome of a transplantation procedure.

This invention is directed to novel oxamyl dipeptide ICE / ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

A method for producing a regenerative organ germ for transplantation includes using regenerative organ germ for transplantation ensuring continuity with a recipient after transplantation and facilitating transplantation procedures. A method for producing a regenerative organ germ provided with a guide for transplantation includes preparing a regenerative organ germ by closely contacting a first cell mass, which substantially consists of mesenchymal cells, and a second cell mass, which substantially consists of epithelial cells, culturing these cell masses within a support, and inserting the guide into the regenerative organ germ.

A surface contour gauge is provided for use in surgical transplantation procedures. Surface contour gauges provide quick and efficient surface contour matches between a patient's bone defect and a prepared allograft plug.

The invention provides a cultivation method capable of preventing Angelica sinensis from premature bolting. The cultivation method comprises the following steps: deeply plowing soil and fertilizing at a planting area; sowing when the temperature of soil layer of 5 cm below the ground surface is 6-8 DEG C, wherein the row spacing is 20-25 cm, opening shallow gullies with the depth of 2-3 cm, after sowing, covering wet soil, and then covering wheatgrass, wherein the seedling density per hectare is 0.45-0.75 million plants, and the plant spacing is 5-10 cm; when the height of seedling is 3-4 cm, gapping and establishing so as to keep the plant spacing and the seedling density; sowing in late October of the present year, digging and sunning when the aerial part is withered so as to obtain the Angelica sinensis. According to the cultivation method, under the precondition of ensuring the yield and quality of Angelica sinensis, the Angelica sinensis is prevented from premature bolting, the seedling and transplantation procedures of Angelica sinensis are omitted, the production period of Angelica sinensis is shortened, 25% of seedling and seedling storage land is saved, and 120-130 days of production period of Angelica sinensis are shortened.

Disclosed herein are anti-CD45 antibodies, antigen-binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. The antibodies and ADCs can be used in therapeutic methods including methods of depleting CD45 + cells in a patient. The compositions and methods described herein can be used for direct treatment of conditions, for example, by depleting CD45 + cancer cells or populations of autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplantation therapy and to improve the implantation of hematopoietic stem cell grafts by selectively depleting endogenous CD45 + cells prior to the transplantation procedure.

The invention relates to methods for promoting maturation of islet cells from pre-weaned mammals for the purpose of optimizing the islets for their use as donor tissue for xenotransplantation. The method of the invention removes the pancreas from donor animals and reduces the pancreas tissue to fragments that are greater than the size of an intact islet while retaining islets in their whole, insulin-producing condition. The method of the invention also serially cultures the digested tissue in novel maturation media that enhance the glucose responsiveness of the cultured islets, and selects islets that are sufficiently glucose-responsive for use in transplantation procedures.

The present invention relates to a method for preparing commercial scale quantities of human functional Betacells and to the establishment of cell lines. It also relates to a method of diagnosis using Beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating Betacells, allowing to generate human Betacell lines. Such lines express little amount of insulin and have a gene expression profile that resembles to adult Betacells. In addition, the human Betacell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities.

Disclosed are methods and compositions which may be utilized to inhibit and / or deplete non-classical monocytes during a transplantation procedure. The disclosed methods and compositions may be utilized in order to reduce damage to organs and tissues during a transplantation procedure and / or to improve the success rate of the transplantation procedure.